Test Information Sheet
|
|
- Derrick Wilkerson
- 7 years ago
- Views:
Transcription
1 Test Information Sheet GeneDx 207 Perry Parkway Gaithersburg, MD Phone: Fax: OncoGene Dx: High/Moderate Risk Panel Sequence Analysis and/or Exon Level Deletion/Duplication Testing of 23 Genes OncoGene Dx High/Moderate Risk Panel Gene List: APC BRCA2 EPCAM^ PALB2 SMAD4 ATM BPRIP1 MLH1 PMS2 STK11 BMPR1A CDH1 MSH2 PTEN TP53 BRCA1 CDKN2A MSH6 RAD51C VHL CHEK2 MUTYH RAD51D ^Next generation sequencing of this gene is not included in this panel. Clinical Features and Genetics: Cancer is a common disease affecting approximately 1 in 3 individuals in the U.S (SEER). While the majority of cancers are sporadic in nature, some families have hereditary forms of cancer that are associated with increased cancer risks compared with the general population. Approximately 5 10% of cancer cases are thought to be due to a hereditary predisposition. The features of a personal and/or family history of cancer that are suggestive of a hereditary cancer predisposition include: young ages at diagnosis, multiple primary cancers in a single individual, and several relatives affected with the same type of cancer or related cancers spanning multiple generations. For some of the well described hereditary conditions discussed below, clinical diagnostic criteria, based on personal medical history and family history, are available to help identify patients most likely to have a hereditary cancer syndrome. In many cases, however, patients do not meet the clinical diagnostic criteria or the criteria may overlap for multiple conditions, making it difficult to decide which genes should be tested and in what order. The OncoGeneDx High/Moderate Risk Panel offered at GeneDx includes analysis of 23 genes associated with hereditary predisposition to various cancers including the most well known hereditary cancer syndromes such as Hereditary Breast and Ovarian Cancer Syndrome (BRCA1, BRCA2) and Lynch Syndrome (MLH1, MSH2, MSH6, PMS2 and EPCAM) as well as moderately penetrant genes including ATM, BRIP1, CHEK2, RAD51C and RAD51D. Many of the genes on this panel are involved in the mismatch repair pathway, the Fanconi anemia pathway and/or play a role in DNA damage repair. All of the genes included on the OncoGeneDx High/Moderate Risk Panel are associated with dominantly inherited cancer risk with the exception of MUTYH associated polyposis which is recessively inherited. The level of cancer risk, relative to general population risk, that is associated with pathogenic variants in each of the genes is outlined in the attached table. With respect to medical management, all of the genes on the OncoGeneDx High/Moderate Risk Panel are discussed specifically in published guidelines such as the NCCN Genetic/Familial High Risk Assessment: Breast/Ovarian or Colorectal. Many of these dominantly associated genes are also associated with an autosomal recessive syndrome if an individual inherits two pathogenic variants in the same gene, one from each parent. For example, if both mother and father are carriers of pathogenic BRCA2 variants, each of their children would have a 25% chance to inherit both pathogenic variants, a 50% chance to inherit one of the pathogenic variants, and a 25% chance to inherit neither pathogenic variant. If a child inherited both pathogenic BRCA2 variants, they would have a rare condition called Fanconi anemia characterized by an increased risk for malignancy in children including leukemia and certain solid Information Sheet on High/Moderate Risk Panel Page 1 of 5 GeneDx Revision Date: 07/2016
2 tumors as well as physical abnormalities and bone marrow failure. All genes that have an associated recessive condition are noted in the attached table. Reason for referral: In addition to the features of hereditary cancer predisposition described above, a next generation sequencing panel for high/moderate risk genes may be especially helpful in cases in which: 1) The differential diagnosis includes various hereditary cancer syndromes. For example, if the family history consists of multiple cases of ovarian cancer, this may be associated with a breast/ovarian cancer syndrome such as BRCA1 or BRCA2 or Lynch syndrome (MLH1, MSH2, MSH6, PMS2, and EPCAM). Thus, the OncoGeneDx High/Moderate Risk Panel offers increased clinical sensitivity compared to testing only for the BRCA1/2 genes. Furthermore, panel testing is more cost effective than stepwise genetic testing (for example, ordering BRCA1/2 testing followed by additional genetic testing). 2) The family history includes a number of cancer cases, but they are of several different types. Therefore, the pattern does not seem to fit any one hereditary cancer syndrome in particular. 3) Some genetic testing has already been ordered due to a family history suggestive of a hereditary cancer predisposition, and results have been negative. OncoGeneDx High/Moderate Risk Panel includes five recently described, but well studied, cancer predisposition genes (ATM, BRIP1, CHEK2, RAD51C and RAD51D) in addition to genes associated with classic hereditary cancer syndromes, and may allow for detection of a causative pathogenic variant after initial testing is uninformative. Methods: Genomic DNA from the submitted specimen was enriched for the complete coding region and splice site junctions of the genes on the panel using a proprietary targeted capture system developed by GeneDx. For PTEN, nucleotides c. 700 through c in the promoter region are also sequenced. The products were sequenced on either an Illumina MiSeq or HiSeq instrument with 2x150 or 2x100 paired end reads, respectively. The sequence was aligned to reference sequences based on human genome build GRCh37/UCSC hg19. Capillary sequencing was used to confirm all variants with clinical or uncertain significance and to analyze regions with inadequate coverage by Next Generation sequencing. If present, apparently homozygous variants were confirmed using alternate primer pairs to significantly reduce the possibility of allele drop out. Concurrent deletion/duplication testing was performed for all of the genes on the panel using either exon level array CGH or MLPA. Confirmation of copy number changes was performed by MLPA, qpcr, or repeat acgh analysis. Data analysis was performed using gene specific filtering. The array was designed to detect most single exon deletions and duplications. For EPCAM, deletion/duplication analysis, but not sequencing, was performed. All sequence alterations are described according to the Human Genome Variation Society (HGVS) nomenclature guidelines. Benign and likely benign variants, if present, are not reported but are available upon request. The genes evaluated by this test are listed on the first page of the report. Test Performance: DNA sequencing will detect nucleotide substitutions and small insertions and deletions, while array CGH will detect exon level deletions and duplications. These methods are expected to be greater than 99% sensitive in detecting pathogenic variants identifiable by sequencing or array CGH. The likelihood of a false positive result is expected to be <1%. Technical Limitations: Neither sequencing nor exon level acgh can reliably detect mosaicism, and cannot detect chromosomal aberrations. Deletions involving more than 20bp and insertions involving more than 10bp are not reliably detected by the sequencing methodology, and deletions or duplications of less than 250bp are not reliably detected by array CGH. Regions of certain genes have inherent sequence properties that yield suboptimal data, potentially impairing accuracy of the results. For instance, sequence and deletion/duplication analysis of PMS2 and Information Sheet on High/Moderate Risk Panel Page 2 of 5 GeneDx Revision Date: 07/2016
3 CHEK2, among others, is complicated by the presence of pseudogenes or homologous sequences that involve multiple exons of these genes. In the absence of mrna/cdna studies, we cannot completely exclude the possibility of undetectable clinically significant variants in certain regions of these genes. Specifically, large deletions or duplications in PMS2 exons 2 5, 9, and will not be detectable due to the presence of pseudogenes. False negatives may also occur in the setting of bone marrow transplantation, recent blood transfusion, or suboptimal DNA quality. In individuals with active leukemia or lymphoma or with known chronic myeloid or lymphoid neoplasms (such as low grade MDS, CML, ET, P. vera, PMF, CLL), there is a possibility that testing of specimens containing leukocytes may detect an acquired somatic variant, resulting in a false positive result. In this situation, please contact one of our genetic counselors to discuss the utility of submitting an alternate specimen. Additionally, rare false negatives may occur when testing for a specific variant identified at a laboratory other than GeneDx if a positive control is not provided. Based on the specific array design and technology used, the reported coordinates of duplications and deletions at the exon or gene level can slightly differ among family members tested but, in general, relatives are expected to have the same copy number variant. The ability to detect genetic variants and naming conventions can differ among laboratories. Reporting of Results: Results will be interpreted and reported following recommendations of the American College of Medical Genetics as a guideline ( Variations detected by sequencing or deletion/duplication analysis will be analyzed and classified into the following categories based on current scientific knowledge. Our analysis includes a comprehensive assessment of the variation on a molecular and clinical level in order to determine its clinical significance and classification. Trained PhD analysts perform a detailed review of the variation on the molecular level, including exhaustive searches of gene and locus specific databases and the Human Gene Mutation Database (HGMD), and genetic counselors and clinical molecular geneticists carefully review literature reports. Pathogenic Variant Examples of variations that may be reported as pathogenic include frameshift variants and nonsense variants that are predicted to result in premature protein truncation or mrna decay, canonical splice site variants, and previously reported missense variants that are recognized as disease causing. Likely Pathogenic Variant Variations for which there is significant, but not conclusive, evidence supporting pathogenicity will be classified as Likely Pathogenic. Variant of Uncertain Significance Variations for which there is not sufficient evidence for classification will be classified as Variant of Uncertain Significance. Negative No variation of clinical or uncertain significance was detected. Any variation detected and classified as a likely benign or benign variant based on population data, review of the literature, Human Gene Mutation Database (HGMD), and appropriate locus specific databases will not be reported. Specimen Requirements and Shipping/Handling: Blood: Two EDTA (lavender top) tubes containing 4 ml each whole sterile blood Oral Rinse: Saliva collect in 30mL of mouthwash using our GeneDx collection kit Extracted DNA: >20 ug Buccal Swab: For family member testing only (excluding deletion/duplication family testing) Information Sheet on High/Moderate Risk Panel Page 3 of 5 GeneDx Revision Date: 07/2016
4 Test Codes and Turnaround Times Please contact us for price information: Test Code Description Turnaround Time B751 High/Moderate Risk Panel 3 weeks References Canto MI et al. International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut Mar;62(3): (PMID ) Frantzen C et al. Von Hippel Lindau Syndrome May 17 [Updated 2015 Aug 6]. In: Pagon RA, Adam MP, Ardinger HH, et al., editors. GeneReviews [Internet]. Seattle (WA): University of Washington, Seattle; Available from: National Cancer Institute at the National Institutes of Health. What you need to know about: cancer; risk factors. (URL: cancer) [February 2016 accessed]. NCCN Guidelines. Gastric Cancer. (URL: [February 2016 accessed]. NCCN Guidelines. Genetic/Familial High Risk Assessment: Breast and Ovarian. (URL: [February 2016 accessed]. NCCN Guidelines. Genetic/Familial High Risk Assessment: Colorectal. (URL: [February 2016 accessed]. Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute. SEER Cancer Statistics Review, : Lifetime Risk Tables (URL: [February 2016 accessed]. Gene Most commonly associated cancers Associated recessive syndrome Management Guidelines APC NM_ BMPR1A NM_ BRCA1 NM_ BRCA2 NM_ CDH1 NM_ CDKN2A NM_ NM_ EPCAM NM_ MLH1 NM_ MSH2 NM_ MSH6 NM_ MUTYH NM_ PALB2 NM_ PMS2 NM_ PTEN NM_ SMAD4 NM_ STK11 NM_ TP53 NM_ VHL NM_ ATM NM_ Colon, Small Bowel Colon, Gastric (if gastric polyps) High Risk Genes Breast, Ovarian, Pancreatic, Prostate, Endometrial serous carcinoma^ Breast, Ovarian, Pancreatic, Prostate, Endometrial serous carcinoma^ Gastric, Breast, Colon (signet ring)^ Fanconi anemia, CAPS #, NCCN Gastric Melanoma, Pancreatic CAPS # Colon, Endometrial, Ovarian^, Gastric^ Colon, Endometrial, Ovarian, Gastric, Pancreatic Colon, Endometrial, Ovarian, Gastric, Colon, Endometrial,Ovarian, Gastric^ Colon, Small Bowel, Endometrial serous carcinoma ^ MUTYH associated polyposis Breast, Pancreatic (possibly high risk)^ Fanconi anemia, CAPS # Colon, Endometrial, Ovarian^, Gastric^ Breast, Thyroid, Endometrial Colon, Gastric (if gastric polyps) Breast, Colon, Pancreatic, Gastric, Small Bowel, Endometrial Breast, Sarcoma, Brain, Hematologic malignancies, Adrenocortical, among others* Renal, Pancreatic neuroendocrine tumors, Hemangioblastoma, Pheochromocytoma Moderate Risk Genes,, CAPS # VHL GeneReviews (Frantzen 2000) Breast, Colon^, Ataxia telangiectasia Information Sheet on High/Moderate Risk Panel Page 4 of 5 GeneDx Revision Date: 07/2016
5 BRIP1 NM_ CHEK2 NM_ RAD51C NM_ RAD51D NM_ Breast^, Ovarian^ Fanconi anemia Breast, Prostate (possibly high risk)^, Colon^, Breast^, Ovarian^ Fanconi anemia Breast^, Ovarian^ Key Red font denotes significantly increased cancer risk. We consider significantly increased risk to be a relative risk of 4 or higher in relation to the general population risk. This translates to the following lifetime cancer risks: 50% breast cancer, 20% colon cancer, 11% endometrial cancer, 8% melanoma, 7% renal cancer, 6% pancreatic cancer, 6% ovarian cancer, 5% thyroid cancer, 4% gastric or small bowel cancer. Blue font denotes moderately increased cancer risk. We consider moderately increased risk to be a relative risk between 2 and 4 in relation to the general population risk. This translates to the following lifetime cancer risks: 24 49% breast cancer, 32 60% prostate cancer, 5 11% endometrial cancer, 3 6% pancreatic cancer. ^ Gene specific risk for this cancer type is not well defined. * High overall risk of cancer: 75% lifetime risk for males to develop cancer, nearly 100% risk for females. # CAPS International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer (Canto 2013). Information Sheet on High/Moderate Risk Panel Page 5 of 5 GeneDx Revision Date: 07/2016
Test Information Sheet
Test Information Sheet GeneDx 207 Perry Parkway Gaithersburg, MD 20877 Phone: 888-729-1206 Fax: 301-710-6594 E-mail: wecare@genedx.com www.genedx.com/oncology OncoGene Dx: Breast/Ovarian Cancer Panel Sequence
More informationCommon Cancers & Hereditary Syndromes
Common Cancers & Hereditary Syndromes Elizabeth Hoodfar, MS, LCGC Regional Cancer Genetics Coordinator Kaiser Permanente Northern California Detect clinical characteristics of hereditary cancer syndromes.
More informationHereditary Breast Cancer Panels. High Risk Hereditary Breast Cancer Panel Hereditary Breast/Ovarian/Endometrial Cancer Panel
P A T I E N T G U I D E Hereditary Breast Cancer Panels High Risk Hereditary Breast Cancer Panel Hereditary Breast/Ovarian/Endometrial Cancer Panel B a y l o r M i r a c a G e n e t i c s L a b o r a t
More informationHereditary Breast Cancer Testing. Diagnostic
Hereditary Cancer Testing Diagnostic New solutions for hereditary breast cancer. Identifying and understanding the genetic contribution to breast cancer allows for individualized disease management and
More informationThe Genetics of Early- Onset Breast Cancer. Cecelia Bellcross, Ph.D., M.S.,C.G.C. Department of Human Genetics Emory University School of Medicine
The Genetics of Early- Onset Breast Cancer Cecelia Bellcross, Ph.D., M.S.,C.G.C. Department of Human Genetics Emory University School of Medicine All cancers are genetic BUT Not all cancers are hereditary
More informationGenetics and Breast Cancer. Elly Lynch, Senior Genetic Counsellor Manager, Austin Health Clinical Genetics Service
Genetics and Breast Cancer Elly Lynch, Senior Genetic Counsellor Manager, Austin Health Clinical Genetics Service Overview Background/Our Team What is the difference between sporadic/familial cancer? How
More informationOvarian Cancer Genetic Testing: Why, When, How?
Ovarian Cancer Genetic Testing: Why, When, How? Jeffrey Dungan, MD Associate Professor Division of Clinical Genetics Department of Obstetrics & Gynecology Northwestern University Feinberg School of Medicine
More information6/10/2015. Hereditary Predisposition for Breast Cancer: Looking at BRCA1/BRCA2 Testing & Beyond. Hereditary Cancers. BRCA1 and BRCA2 Review
Hereditary Predisposition for Breast Cancer: Looking at BRCA1/BRCA2 Testing & Beyond Arturo Anguiano MD, FACMG International Medical Director, Medical Affairs Vice Chairman, Genetics; Medical Director,
More informationA Decision Support Tool to Facilitate Cancer Risk Assessment and Referral for Genetics Services. Kristen Vogel Postula, MS, CGC & Leigh Baumgart, PhD
A Decision Support Tool to Facilitate Cancer Risk Assessment and Referral for Genetics Services Kristen Vogel Postula, MS, CGC & Leigh Baumgart, PhD Importance of Family History Increasing awareness of
More informationAdvice about familial aspects of breast cancer and epithelial ovarian cancer a guide for health professionals DECEMBER 2010
Advice about familial aspects of breast cancer and epithelial ovarian cancer a guide for health professionals DECEMBER 2010 This guide has three parts: 1. Information for health professionals 2. Tables
More informationBRCA in Men. Mary B. Daly,M.D.,Ph.D. June 25, 2010
BRCA in Men Mary B. Daly,M.D.,Ph.D. June 25, 2010 BRCA in Men Inheritance patterns of BRCA1/2 Cancer Risks for men with BRCA1/2 mutations Risk management recommendations for men with BRCA1/2 mutations
More informationPancreatic Cancer. Hereditary Pancreatic Cancer A Guide for Clinicians KNOWING WHAT TO LOOK FOR KNOWING WHERE TO LOOK AND KNOWING WHAT IT MEANS
Pancreatic Cancer Hereditary Pancreatic Cancer A Guide for Clinicians KNOWING WHAT TO LOOK FOR KNOWING WHERE TO LOOK AND KNOWING WHAT IT MEANS Hereditary Pancreatic Cancer Panel Advances in molecular genetics
More informationOverview of testing for Lynch syndrome/hnpcc
Overview of testing for Lynch syndrome/hnpcc This overview provides detailed information about interpreting MSI/IHC testing and genetic testing for Lynch syndrome/hnpcc. It is intended to be a reference
More informationBeyond BRCA the Future is Now
Beyond BRCA the Future is Now Richard P. Frieder, MD Medical Director, Intelegene Assistant Clinical Professor Department of Obstetrics and Gynecology David Geffen School of Medicine, UCLA University of
More informationBreast cancer and the role of low penetrance alleles: a focus on ATM gene
Modena 18-19 novembre 2010 Breast cancer and the role of low penetrance alleles: a focus on ATM gene Dr. Laura La Paglia Breast Cancer genetic Other BC susceptibility genes TP53 PTEN STK11 CHEK2 BRCA1
More informationMUTATION, DNA REPAIR AND CANCER
MUTATION, DNA REPAIR AND CANCER 1 Mutation A heritable change in the genetic material Essential to the continuity of life Source of variation for natural selection New mutations are more likely to be harmful
More informationGENETIC CONSIDERATIONS IN CANCER TREATMENT AND SURVIVORSHIP
GENETIC CONSIDERATIONS IN CANCER TREATMENT AND SURVIVORSHIP WHO IS AT HIGH RISK OF HEREDITARY CANCER? Hereditary Cancer accounts for a small proportion of all cancer or approximately 5-10% THE DEVELOPMENT
More informationIMMEDIATE HOT LINE: Effective March 2, 2015
MEDICARE COVERAGE OF LABORATORY TESTING Please remember when ordering laboratory tests that are billed to Medicare/Medicaid or other federally funded programs, the following requirements apply: 1. Only
More informationCancer: Genetic testing can save lives
Cancer: Genetic testing can save lives Track chances of having a tumor's tendency among people with a history of disease cases in the family, but practice should not be trivialized and hurt even more who
More informationBreast and Ovarian Cancer
Breast and Ovarian Cancer Hereditary Breast and Ovarian Cancer A Guide for Clinicians KNOWING WHAT TO LOOK FOR KNOWING WHERE TO LOOK AND KNOWING WHAT IT MEANS Hereditary Breast and Ovarian Cancer Panel
More informationCorporate Medical Policy Genetic Testing for Fanconi Anemia
Corporate Medical Policy Genetic Testing for Fanconi Anemia File Name: Origination: Last CAP Review: Next CAP Review: Last Review: genetic_testing_for_fanconi_anemia 03/2015 3/2016 3/2017 3/2016 Description
More informationGenetic Testing for Lynch Syndrome/Colorectal Cancer and Polyposis Syndromes
Genetic Testing for Lynch Syndrome/Colorectal Cancer and Polyposis Syndromes Policy Number: Original Effective Date: MM.02.007 09/01/2011 Line(s) of Business: Current Effective Date: HMO; PPO 09/01/2011
More informationProgress and Prospects in Ovarian Cancer Screening and Prevention
Progress and Prospects in Ovarian Cancer Screening and Prevention Rebecca Stone, MD MS Assistant Professor Kelly Gynecologic Oncology Service The Johns Hopkins Hospital 1 No Disclosures 4/12/2016 2 Ovarian
More informationLecture 3: Mutations
Lecture 3: Mutations Recall that the flow of information within a cell involves the transcription of DNA to mrna and the translation of mrna to protein. Recall also, that the flow of information between
More informationNEIGE. diagnosis In oncogenetics. Nicolas Sévenet 02 juillet 2012. n.sevenet@bordeaux.unicancer.fr
NEIGE g for molecular NExt g generation sequencing diagnosis In oncogenetics Nicolas Sévenet 02 juillet 2012 n.sevenet@bordeaux.unicancer.fr t@b d i f Reports 15 years Next generation sequencing 06/2011
More informationGenetic Testing for Familial Adenomatous Polyposis and MYH-Associated Polyposis (Lynch Syndrome)
Harmony Behavioral Health, Inc. Harmony Behavioral Health of Florida, Inc. Harmony Health Plan of Illinois, Inc. HealthEase of Florida, Inc. Ohana Health Plan, a plan offered by WellCare Health Insurance
More informationpatient guide BRCA1 and BRCA2 Genetic Testing for Hereditary Breast and Ovarian Cancer
patient guide BRCA1 and BRCA2 Genetic Testing for Hereditary Breast and Ovarian Cancer What is hereditary cancer? Cancer affects many people in the U.S.: breast cancer affects 1 in 8 women and ovarian
More informationBRCA1 & BRCA2 GeneHealth UK
BRCA1 & BRCA2 GeneHealth UK BRCA1 & BRCA2 What is hereditary breast cancer? Cancer is unfortunately very common, with 1 in 3 people developing cancer at some point in their lifetime. Breast cancer occurs
More informationBRCA1 and BRCA2. BRCA1 and BRCA2 Clinician Guide KNOWING WHAT TO LOOK FOR KNOWING WHERE TO LOOK AND KNOWING WHAT IT MEANS
BRCA1 and BRCA2 BRCA1 and BRCA2 Clinician Guide KNOWING WHAT TO LOOK FOR KNOWING WHERE TO LOOK AND KNOWING WHAT IT MEANS BRCA1 and BRCA2 Breast cancer is the most common cancer in women, diagnosed in
More informationDal germinale al somatico nella identificazione di tumori ereditari
Modena 18-19 novembre 2010 Dal germinale al somatico nella identificazione di tumori ereditari Laura Ottini Tendencies to develop cancer can be inherited Fletcher & Houlston, 2010 Cancer is a genetic disease
More informationGenetic Testing for Susceptibility to Breast and Ovarian Cancer (BRCA1 and BRCA 2)
Easy Choice Health Plan, Inc. Harmony Health Plan of Illinois, Inc. M issouri Care, Inc. Ohana Health Plan, a plan offered by WellCare Health Insurance of Arizona, Inc. WellCare Health Insurance of Illinois,
More informationPROVIDER POLICIES & PROCEDURES
PROVIDER POLICIES & PROCEDURES BRCA GENETIC TESTING The purpose of this document is to provide guidance to providers enrolled in the Connecticut Medical Assistance Program (CMAP) on the requirements for
More informationTEST AND PRICE LIST FOR NEXT GENERATION SEQUENCING
AIP ALK APC Mutation Detection Techniques Ai Saple Type TAT ATM BAP1 BLM BMPR1A BRCA1 BRCA2 BRIP1 BUB1B CDC73 CDH1 CDK4 CDKN1C CDKN2A CEBPA CEP57 CHEK2 CYLD DDB2 DICER1 DIS3L2 EGFR EPCAM ERCC2 ERCC3 ERCC4
More informationHereditary Breast Cancer. Nicole Kounalakis, MD Assistant Professor of Surgery University of Colorado Medical Center
Hereditary Breast Cancer Nicole Kounalakis, MD Assistant Professor of Surgery University of Colorado Medical Center Outline Background Assessing risk of patient Syndromes BRCA 1,2 Li Fraumeni Cowden Hereditary
More informationGenomic Medicine Education Initiatives of the College of American Pathologists
Genomic Medicine Education Initiatives of the College of American Pathologists Debra G.B. Leonard, MD, PhD, FCAP Chair, Personalized Healthcare Committee, CAP Professor of Pathology, Weill Cornell Medical
More informationName of Policy: Genetic Testing for Hereditary Breast and/or Ovarian Cancer
Name of Policy: Genetic Testing for Hereditary Breast and/or Ovarian Cancer Policy #: 513 Latest Review Date: January 2014 Category: Laboratory Policy Grade: B Background/Definitions: As a general rule,
More informationSpecial report. Chronic Lymphocytic Leukemia (CLL) Genomic Biology 3020 April 20, 2006
Special report Chronic Lymphocytic Leukemia (CLL) Genomic Biology 3020 April 20, 2006 Gene And Protein The gene that causes the mutation is CCND1 and the protein NP_444284 The mutation deals with the cell
More informationUnderstanding Your Risk of Ovarian Cancer
Understanding Your Risk of Ovarian Cancer A WOMAN S GUIDE This brochure is made possible through partnership support from Project Hope for Ovarian Cancer Research and Education. Project HOPE FOR OVARIAN
More informationPrevention GENEration. The Importance of Genetic Testing for Hereditary Breast and Ovarian Cancer Syndrome (HBOC)
הסיכוי שבסיכון PREVENTION GENERATION Prevention GENEration The Importance of Genetic Testing for Hereditary Breast and Ovarian Cancer Syndrome (HBOC) We thank Prof. Ephrat Levy-Lahad Director, Medical
More informationGENETIC TESTING FOR INHERITED MUTATIONS OR SUSCEPTIBILITY TO CANCER OR OTHER CONDITIONS MED207.110
GENETIC TESTING FOR INHERITED MUTATIONS OR SUSCEPTIBILITY TO CANCER OR OTHER CONDITIONS MED207.110 COVERAGE: Pre- and post-genetic test counseling may be eligible for coverage in addition to the genetic
More informationWhat is Cancer? Cancer is a genetic disease: Cancer typically involves a change in gene expression/function:
Cancer is a genetic disease: Inherited cancer Sporadic cancer What is Cancer? Cancer typically involves a change in gene expression/function: Qualitative change Quantitative change Any cancer causing genetic
More informationInformation leaflet. Centrum voor Medische Genetica. Version 1/20150504 Design by Ben Caljon, UZ Brussel. Universitair Ziekenhuis Brussel
Information on genome-wide genetic testing Array Comparative Genomic Hybridization (array CGH) Single Nucleotide Polymorphism array (SNP array) Massive Parallel Sequencing (MPS) Version 120150504 Design
More informationNumber 12.04.516 Effective Date August 11, 2015 Revision Date(s) Replaces 2.04.133 (not adopted)
MEDICAL POLICY POLICY RELATED POLICIES POLICY GUIDELINES DESCRIPTION SCOPE BENEFIT APPLICATION RATIONALE REFERENCES CODING APPENDI HISTORY Genetic Testing for CHEK2 Mutations for Breast Cancer Number 12.04.516
More informationGenE EMR-Genome Enabled Electronic Medical Record for Clinicians and Citizens
GenE EMR-Genome Enabled Electronic Medical Record for Clinicians and Citizens A GenE EMR is an EMR that provides access to clinical data so Internet based applications such as Health Heritage can: Collect,
More informationContents. molecular biology techniques. - Mutations in Factor II. - Mutations in MTHFR gene. - Breast cencer genes. - p53 and breast cancer
Contents Introduction: biology and medicine, two separated compartments What we need to know: - boring basics in DNA/RNA structure and overview of particular aspects of molecular biology techniques - How
More informationGynecologic Cancer in Women with Lynch Syndrome
Gynecologic Cancer in Women with Lynch Syndrome Sarah E. Ferguson, MD FRCSC Division of Gynecologic Oncology, Princess Margaret Hospital, University of Toronto June 11, 2013 Objective 1. To review the
More informationEstimated New Cases of Leukemia, Lymphoma, Myeloma 2014
ABOUT BLOOD CANCERS Leukemia, Hodgkin lymphoma (HL), non-hodgkin lymphoma (NHL), myeloma, myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPNs) are types of cancer that can affect the
More informationgenetic &testing * VC: Explain more about genetic counseling for pancreatic cancer. What s involved?
volume III/winter 2009 Harold Frucht, M.D. genetic counseling &testing * Virginia Cravotta (VC): Please define genetics and genetic testing, and explain how testing might be useful to individuals concerned
More informationGenetic Testing for CHEK2 Mutations for Breast Cancer
Genetic Testing for CHEK2 Mutations for Breast Cancer Policy Number: 2.04.133 Last Review: 8/2015 Origination: 8/2015 Next Review: 8/2016 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will
More informationName of Policy: Genetic Testing for Inherited Cancer Predisposition and/or Pharmacogenetics related to Cancer Treatment
Name of Policy: Genetic Testing for Inherited Cancer Predisposition and/or Pharmacogenetics related to Cancer Treatment Policy #: 133 Latest Review Date: April 2015 Category: Laboratory Policy Grade: D
More informationNew Hampshire Childhood Cancer
Introduction: New Hampshire Childhood Cancer New Hampshire, Childhood Cancer, January 2009 Issue Brief Cancer in children is relatively uncommon, impacting fewer than twenty two of every 100,000 children
More informationMedicare Coverage of Genomic Testing
Medicare Coverage of Genomic Testing Louis B. Jacques, MD Director, DID/CAG/OCSQ With acknowledgements to Jeff Roche, MD Social Security Act 1862(a)(1)(A) Notwithstanding any other provision of this title,
More information1 Mutation and Genetic Change
CHAPTER 14 1 Mutation and Genetic Change SECTION Genes in Action KEY IDEAS As you read this section, keep these questions in mind: What is the origin of genetic differences among organisms? What kinds
More informationGenetic Counseling and Testing: Cancer Genetics
KAISER PERMANENTE HAWAII CLINICAL PRACTICE GUIDELINE Genetic Counseling and Testing: Cancer Genetics QUALITY COMMITTEE ADOPTION DATE: October 2015 LAST REVIEW DATE: September 2015 NEXT SCHEDULED REVIEW
More informationBRCA1 and BRCA2 for men
Oxford University Hospitals NHS Trust Oxford Regional Genetic Department BRCA1 and BRCA2 for men Information for men from families with a known alteration in the BRCA1/2 gene Introduction BRCA1 and BRCA2
More informationpatient education Fact Sheet PFS007: BRCA1 and BRCA2 Mutations MARCH 2015
patient education Fact Sheet PFS007: BRCA1 and BRCA2 Mutations MARCH 2015 BRCA1 and BRCA2 Mutations Cancer is a complex disease thought to be caused by several different factors. A few types of cancer
More informationRisk stratification for colorectal cancer especially: the difference between sporadic disease and polyposis syndromes. Dr. med. Henrik Csaba Horváth
Risk stratification for colorectal cancer especially: the difference between sporadic disease and polyposis syndromes Dr. med. Henrik Csaba Horváth Why is risk stratification for colorectal cancer (CRC)
More informationREQUEST FOR IMAGe SYNDROME TESTING
REQUEST FOR IMAGe SYNDROME TESTING Please provide the following information. We cannot perform your test without ALL of this information. PLEASE PRINT ALL ANSWERS PATIENT INFORMATION* FIRST NAME MI LAST
More informationHuman Genome Organization: An Update. Genome Organization: An Update
Human Genome Organization: An Update Genome Organization: An Update Highlights of Human Genome Project Timetable Proposed in 1990 as 3 billion dollar joint venture between DOE and NIH with 15 year completion
More informationCHROMOSOMES Dr. Fern Tsien, Dept. of Genetics, LSUHSC, NO, LA
CHROMOSOMES Dr. Fern Tsien, Dept. of Genetics, LSUHSC, NO, LA Cytogenetics is the study of chromosomes and their structure, inheritance, and abnormalities. Chromosome abnormalities occur in approximately:
More informationMedical Policy Manual. Topic: Genetic Testing for Hereditary Breast and/or Ovarian Cancer. Date of Origin: January 27, 2011
Medical Policy Manual Topic: Genetic Testing for Hereditary Breast and/or Ovarian Cancer Date of Origin: January 27, 2011 Section: Genetic Testing Last Reviewed Date: May 2015 Policy No: 02 Effective Date:
More informationThis fact sheet describes how genes affect our health when they follow a well understood pattern of genetic inheritance known as autosomal recessive.
11111 This fact sheet describes how genes affect our health when they follow a well understood pattern of genetic inheritance known as autosomal recessive. In summary Genes contain the instructions for
More informationName of Policy: Genetic Testing for Inherited Cancer Predisposition and/or Pharmacogenetics related to Cancer Treatment
Name of Policy: Genetic Testing for Inherited Cancer Predisposition and/or Pharmacogenetics related to Cancer Treatment Policy #: 133 Latest Review Date: April 2015 Category: Laboratory Policy Grade: D
More informationUnderstanding Hereditary Breast and Ovarian Cancer. Maritime Hereditary Cancer Service
Understanding Hereditary Breast and Ovarian Cancer Maritime Hereditary Cancer Service General Information Cancer is very common. About one in three (33%) people are diagnosed with some form of cancer during
More informationGenetic Testing for Hereditary Breast and Ovarian Cancer - BRCA1/2 ANALYSIS -
Genetic Testing for Hereditary Breast and Ovarian Cancer - BRCA1/2 ANALYSIS - January 2005 SCIENTIFIC BACKGROUND Breast cancer is considered to be one of the most prevalent cancer in women. The overall
More informationUnderstanding Lynch Syndrome
ESSENTIALS Lynch Syndrome Understanding Lynch Syndrome Certain cancers can run in families. Sometimes this happens because of harmful changes (called mutations) in our genes that are passed from one generation
More informationBRCA1 & BRCA2: Genetic testing for hereditary breast and ovarian cancer patient guide
BRCA1 & BRCA2: Genetic testing for hereditary breast and ovarian cancer patient guide What is Hereditary? Breast cancer is the most common cancer in women in the U.S. (it affects about 1 in 8 women). Ovarian
More informationNational Medical Policy
National Medical Policy Subject: Policy Number: Genetic Testing for BRCA1 and BRCA2 NMP136 Effective Date*: April 2004 Updated: September 2015 This National Medical Policy is subject to the terms in the
More informationBiochemistry of Cancer Cell
Biochemistry of Cancer Cell Prof. Taha Kumosani Prof. Taha Kumosani http://biochemistry4all.com/taha/5.htm Cancer: an Overview Paleopathologists Dinosaur bones Egyptians Papyrus Autopsis Hippocrates Carcinoma
More informationHereditary Ovarian cancer: BRCA1 and BRCA2. Karen H. Lu MD September 22, 2013
Hereditary Ovarian cancer: BRCA1 and BRCA2 Karen H. Lu MD September 22, 2013 Outline Hereditary Breast and Ovarian Cancer (HBOC) BRCA1/2 genes How to identify What it means to you What it means to your
More information***Next Generation sequencing testing options available effective April 18 th, 2016***
***Next Generation sequencing testing options available effective April 18 th, 2016*** Genetic Test Next Generation Sequencing NF1-RASopathy Panel Testing NF1-only NGS testing and copy number analysis
More informationCHAPTER 2. Neoplasms (C00-D49) March 2014. 2014 MVP Health Care, Inc.
Neoplasms (C00-D49) March 2014 2014 MVP Health Care, Inc. CHAPTER SPECIFIC CATEGORY CODE BLOCKS C00-C14 Malignant neoplasms of lip, oral cavity and pharynx C15-C26 Malignant neoplasms of digestive organs
More information14.3 Studying the Human Genome
14.3 Studying the Human Genome Lesson Objectives Summarize the methods of DNA analysis. State the goals of the Human Genome Project and explain what we have learned so far. Lesson Summary Manipulating
More informationOverview of Genetic Testing and Screening
Integrating Genetics into Your Practice Webinar Series Overview of Genetic Testing and Screening Genetic testing is an important tool in the screening and diagnosis of many conditions. New technology is
More informationGenes and Cancer. What are genes? Dominant vs. recessive genes
Genes and Cancer Advances in science have improved our knowledge of the inner workings of cells, the basic building blocks of the body. All living things are made of cells. Complex animals such as humans
More informationTargeted Variant Test Requisition Form (3/4/2015)
Targeted Variant Test Requisition Form (3/4/2015) Instructions: Please provide clinical features of family members. All testing must be ordered by a qualified healthcare provider. See Test Selection Box
More informationEpi procolon The Blood Test for Colorectal Cancer Screening
Epi procolon The Blood Test for Colorectal Cancer Screening Epi procolon is an approved blood test for colorectal cancer screening. The US Preventive Services Task Force, the American Cancer Society and
More informationPatient Information. for Childhood
Patient Information Genetic Testing for Childhood Hearing Loss Introduction This document describes the most common genetic cause of childhood hearing loss and explains the role of genetic testing. Childhood
More informationMarch 19, 2014. Dear Dr. Duvall, Dr. Hambrick, and Ms. Smith,
Dr. Daniel Duvall, Medical Officer Center for Medicare, Hospital and Ambulatory Policy Group Centers for Medicare and Medicaid Services 7500 Security Boulevard Baltimore, Maryland 21244 Dr. Edith Hambrick,
More informationThe Human Genome Project. From genome to health From human genome to other genomes and to gene function Structural Genomics initiative
The Human Genome Project From genome to health From human genome to other genomes and to gene function Structural Genomics initiative June 2000 What is the Human Genome Project? U.S. govt. project coordinated
More informationAdvances in RainDance Sequence Enrichment Technology and Applications in Cancer Research. March 17, 2011 Rendez-Vous Séquençage
Advances in RainDance Sequence Enrichment Technology and Applications in Cancer Research March 17, 2011 Rendez-Vous Séquençage Presentation Overview Core Technology Review Sequence Enrichment Application
More information***Next Generation sequencing testing options available effective April 18 th, 2016***
***Next Generation sequencing testing options available effective April 18 th, 2016*** Genetic Test Next Generation Sequencing NF1-RASopathy Panel Testing NF1-only NGS testing and copy number analysis
More informationGuidance Document Enhancing cancer genomics practice through education, surveillance and policy Introductions
Guidance Document Enhancing cancer genomics practice through education, surveillance and policy Introductions Georgians of all backgrounds have experienced the devastating impact of cancer. It is the second
More informationBRCA Genes and Inherited Breast and Ovarian Cancer. Patient information leaflet
BRCA Genes and Inherited Breast and Ovarian Cancer Patient information leaflet This booklet has been written for people who have a personal or family history of breast and/or ovarian cancer that could
More informationif your family has a history
if your family has a history OF CANCER. put it to the test. Learn about your risk for hereditary and ovarian and how you can reduce it. do you have a family history of Breast or Ovarian Cancer? what does
More informationColon Cancer Syndromes. Robin B. Mendelsohn MD Memorial Sloan Kettering Cancer Center Department of Medicine Gastroenterology and Nutrition Service
Colon Cancer Syndromes Robin B. Mendelsohn MD Memorial Sloan Kettering Cancer Center Department of Medicine Gastroenterology and Nutrition Service Background: Etiology of Colorectal Cancer (CRC) Sporadic:
More informationMRC-Holland MLPA. Related SALSA MLPA probemix P091 CFTR: contains probes for the CFTR gene, related to chronic pancreatitis.
SALSA MLPA probemix P242-B3 Pancreatitis Lot B3-0215. As compared to version B2 (lot B2-1212), one flanking probe has been removed and four reference probes have been replaced. Hereditary Pancreatitis
More informationPatient Support Guide
Patient Support Guide to genetic testing for hereditary breast and ovarian cancer syndrome Testing for BRCA1 and BRCA2 is available from Quest Diagnostics. Quest Diagnostics Patient Support Guide to Genetic
More informationSection: Genetic Testing Last Reviewed Date: October 2015. Policy No: 73 Effective Date: November 1, 2015
Medical Policy Manual Topic: Genetic Cancer Susceptibility Panels Using Next Generation Sequencing Date of Origin: July 2014 Section: Genetic Testing Last Reviewed Date: October 2015 Policy No: 73 Effective
More informationFrom Immunotherapy of Cancer to the Discovery of Kidney Cancer Genes
ISSN 2154-4006 The Genetic Basis of Human Disease zbar Colloquium series on Series Editor: Michael Dean, Ph.D., Head, Human Genetics Section, Senior Investigator, Laboratory of Experimental Immunology
More informationmicrornas Non protein coding, endogenous RNAs of 21-22nt length Evolutionarily conserved
microrna 2 micrornas Non protein coding, endogenous RNAs of 21-22nt length Evolutionarily conserved Regulate gene expression by binding complementary regions at 3 regions of target mrnas Act as negative
More informationNext Generation Sequencing: Technology, Mapping, and Analysis
Next Generation Sequencing: Technology, Mapping, and Analysis Gary Benson Computer Science, Biology, Bioinformatics Boston University gbenson@bu.edu http://tandem.bu.edu/ The Human Genome Project took
More informationFulfilling the Promise
Fulfilling the Promise Advancing the Fight Against Cancer: America s Medical Schools and Teaching Hospitals For more than a century, the nation s medical schools and teaching hospitals have worked to understand,
More informationData Analysis for Ion Torrent Sequencing
IFU022 v140202 Research Use Only Instructions For Use Part III Data Analysis for Ion Torrent Sequencing MANUFACTURER: Multiplicom N.V. Galileilaan 18 2845 Niel Belgium Revision date: August 21, 2014 Page
More informationG E N OM I C S S E RV I C ES
GENOMICS SERVICES THE NEW YORK GENOME CENTER NYGC is an independent non-profit implementing advanced genomic research to improve diagnosis and treatment of serious diseases. capabilities. N E X T- G E
More informationNOTTINGHAM UNIVERSITY HOSPITAL NHS TRUST NOTTINGHAM BREAST INSTITUTE BREAST AND OVARIAN FAMILY HISTORY GUIDELINES
NOTTINGHAM UNIVERSITY HOSPITAL NHS TRUST NOTTINGHAM BREAST INSTITUTE BREAST AND OVARIAN FAMILY HISTORY GUIDELINES GP Referrals All GP referrals for asymptomatic women with a family history of breast and/or
More informationAbout The Causes of Hearing Loss
About 1 in 500 infants is born with or develops hearing loss during early childhood. Hearing loss has many causes: some are genetic (that is, caused by a baby s genes) or non-genetic (such as certain infections
More informationAP BIOLOGY 2010 SCORING GUIDELINES (Form B)
AP BIOLOGY 2010 SCORING GUIDELINES (Form B) Question 2 Certain human genetic conditions, such as sickle cell anemia, result from single base-pair mutations in DNA. (a) Explain how a single base-pair mutation
More informationScreenWise. Breast, Cervical, and Hereditary Cancer Screenings OCTOBER 28, 2015
ScreenWise Breast, Cervical, and Hereditary Cancer Screenings OCTOBER 28, 2015 ScreenWise Three programs working together to bring quality screening services to Oregon residents Why we all do this work
More informationPROGNOSIS IN ACUTE LYMPHOBLASTIC LEUKEMIA PROGNOSIS IN ACUTE MYELOID LEUKEMIA
PROGNOSIS IN ACUTE LYMPHOBLASTIC LEUKEMIA UNFAVORABLE Advanced age High leukocyte count at diagnosis Presence of myeloid antigens Late achievement of CR Chromosomal abnormalities: t(9:22)(q34:q11) t(4;11)(q21;q23)
More information